| Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia O Agid, B Shapira, J Zislin, M Ritsner, B Hanin, H Murad, T Troudart, ... Molecular psychiatry 4 (2), 163-172, 1999 | 839 | 1999 |
| Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia U Heresco-Levy, DC Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein Archives of general psychiatry 56 (1), 29-36, 1999 | 650 | 1999 |
| The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments RW Buchanan, DC Javitt, SR Marder, NR Schooler, JM Gold, ... American Journal of Psychiatry 164 (10), 1593-1602, 2007 | 528 | 2007 |
| Amelioration of negative symptoms in schizophrenia by glycine. DC Javitt, I Zylberman, SR Zukin, U Heresco-Levy, JP Lindenmayer The American journal of psychiatry 151 (8), 1234-1236, 1994 | 482 | 1994 |
| D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia U Heresco-Levy, DC Javitt, R Ebstein, A Vass, P Lichtenberg, G Bar, ... Biological psychiatry 57 (6), 577-585, 2005 | 419 | 2005 |
| Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia DC Javitt, SR Zukin, U Heresco-Levy, D Umbricht Schizophrenia bulletin 38 (5), 958-966, 2012 | 344 | 2012 |
| Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia U Heresco-Levy, DC Javitt, M Ermilov, C Mordel, A Horowitz, D Kelly The British Journal of Psychiatry 169 (5), 610-617, 1996 | 325 | 1996 |
| Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism B Lerer, RH Segman, H Fangerau, AK Daly, VS Basile, R Cavallaro, ... Neuropsychopharmacology 27 (1), 105-119, 2002 | 302 | 2002 |
| High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia U Heresco-Levy, M Ermilov, P Lichtenberg, G Bar, DC Javitt Biological psychiatry 55 (2), 165-171, 2004 | 282 | 2004 |
| Placebo-Controlled Trial of d-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in Schizophrenia U Heresco-Levy, M Ermilov, J Shimoni, B Shapira, G Silipo, DC Javitt American Journal of Psychiatry 159 (3), 480-482, 2002 | 232 | 2002 |
| Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder U Heresco-Levy, I Kremer, DC Javitt, R Goichman, A Reshef, M Blanaru, ... International Journal of Neuropsychopharmacology 5 (4), 301-307, 2002 | 204 | 2002 |
| Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia RH Segman, U Heresco-Levy, B Finkel, T Goltser, R Shalem, ... Molecular psychiatry 6 (2), 225-229, 2001 | 197 | 2001 |
| Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to … RH Segman, U Heresco-Levy, B Finkel, R Inbar, T Neeman, M Schlafman, ... Psychopharmacology 152, 408-413, 2000 | 182 | 2000 |
| Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia R Segman, T Neeman, U Heresco-Levy, B Finkel, L Karagichev, ... Molecular psychiatry 4 (3), 247-253, 1999 | 179 | 1999 |
| A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression U Heresco-Levy, G Gelfin, B Bloch, R Levin, S Edelman, DC Javitt, ... International Journal of Neuropsychopharmacology 16 (3), 501-506, 2013 | 177 | 2013 |
| The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes U Heresco-Levy, DC Javitt European Neuropsychopharmacology 8 (2), 141-152, 1998 | 167 | 1998 |
| Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia I Kremer, A Vass, I Gorelik, G Bar, M Blanaru, DC Javitt, U Heresco-Levy Biological psychiatry 56 (6), 441-446, 2004 | 151 | 2004 |
| Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis U Heresco-Levy, DC Javitt Schizophrenia research 66 (2-3), 89-96, 2004 | 151 | 2004 |
| Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype B Lerer, RH Segman, EC Tan, VS Basile, R Cavallaro, HN Aschauer, ... International Journal of Neuropsychopharmacology 8 (3), 411-425, 2005 | 146 | 2005 |
| The ethics of the placebo in clinical practice P Lichtenberg, U Heresco-Levy, U Nitzan Journal of Medical Ethics 30 (6), 551-554, 2004 | 145 | 2004 |
